Sign In
Buy CRVS
$11.60
-0.0900 (-0.770%)
At Close: Jun 03, 2026
Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why
01:15pm, Tuesday, 27'th Jan 2026
CRVS stock surges 209% in a month after positive cohort 4 phase I data show durable eczema responses for soquelitinib.
Corvus Pharmaceuticals (CRVS) Is Up 211.80% in One Week: What You Should Know
01:01pm, Tuesday, 27'th Jan 2026
Does Corvus Pharmaceuticals (CRVS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Think Corvus (CRVS) Could Surge 25.29%: Read This Before Placing a Bet
10:56am, Tuesday, 27'th Jan 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 25.3% in Corvus (CRVS). While the effectiveness of this highly sought-after metric is questionable, the positiv
SOUTH SAN FRANCISCO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the closing of an upsized underw
Corvus Pharmaceuticals Shares New Phase I Soquelitinib Data Showing Strong AD EASI Gains
03:02am, Friday, 23'rd Jan 2026
Corvus Pharmaceuticals (NASDAQ: CRVS) presented new Phase I results for oral soquelitinib in moderate-to-severe atopic dermatitis (AD), highlighting updated efficacy, durability, and safety findings f
Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
10:53pm, Wednesday, 21'st Jan 2026
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the pricing of an upsized underw
Corvus Pharmaceuticals: ITK Inhibitor Soquelitinib AD Data Could Be Improved Upon
02:50pm, Wednesday, 21'st Jan 2026
Corvus Pharmaceuticals, Inc. reported highly positive phase 1 cohort 4 data for soquelitinib in moderate-to-severe atopic dermatitis. 75% of patients on 200 mg soquelitinib BID achieved EASI 75, with
Soquelitinib Data Push Corvus Pharmaceuticals Stock Higher: What You Should Know
11:43am, Wednesday, 21'st Jan 2026
Corvus Pharmaceuticals, Inc. stock surged 165% on strong Phase 1 soquelitinib data in moderate-to-severe atopic dermatitis, including treatment-resistant patients. Soquelitinib achieved 75% EASI-75 an
Stock Market Today, Jan. 20: Corvus Pharmaceuticals Surges After Positive Phase 1 Eczema Drug Data
05:57pm, Tuesday, 20'th Jan 2026
Early eczema trial success and heavy trading are rapidly reshaping how investors view this drug developer, today, Jan. 20, 2026.
Corvus Pharmaceuticals, Inc. (CRVS) Discusses Phase 1 Clinical Trial Results of Soquelitinib in Atopic Dermatitis with Focus on Cohort 4 Transcript
Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
04:01pm, Tuesday, 20'th Jan 2026
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwr
What made Corvus stock double on Tuesday and is it sustainable?
02:10pm, Tuesday, 20'th Jan 2026
Corvus Pharmaceuticals (NASDAQ: CRVS) shares more than doubled on Jan. 20 after announcing positive Phase 1 trial data for “soquelitinib” – its oral investigational drug for atopic dermatitis. S
Corvus Stock Spikes On Heels Of Strong Eczema Study Results
02:00pm, Tuesday, 20'th Jan 2026
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) on Tuesday shared data from cohort 4 of the Phase 1 trial evaluating soquelitinib in patients with moderate-to-severe atopic dermatitis.
Why Small Biotech Stock Corvus Pharma Just Launched To An Eight-Year High
10:06am, Tuesday, 20'th Jan 2026
Biotech stock Corvus Pharmaceuticals catapulted to an eight-year high Tuesday on promising results in eczema treatment.
Cohort 4 data demonstrated positive safety and efficacy results, including additional clinical benefit observed following longer 8-week treatment 75% of
